# Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents With Severe, Uncontrolled Asthma

> **NCT03706079** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 951 (actual)

## Conditions studied

- Asthma

## Interventions

- **BIOLOGICAL:** Tezepelumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03706079
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-07
- **Primary completion:** 2021-10-26
- **Final completion:** 2022-05-18
- **Target enrollment:** 951 (ACTUAL)
- **Last updated:** 2023-06-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03706079

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03706079, "Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents With Severe, Uncontrolled Asthma". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03706079. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*